Result of AGM

RNS Number : 8264Z

Syntopix Group plc

20 January 2011

 



Press Release

20 January 2011

Syntopix Group plc

("Syntopix" or "the Company")

Result of AGM

Syntopix Group plc (AIM:SYN), the company focused on topical antimicrobial innovations for products in the medicine and consumer healthcare markets, announces that all resolutions proposed at the Company's Annual General Meeting held today were duly passed.

- Ends -

For further information, please contact:

Syntopix Group plc
Dr Stephen Jones, Chief Executive Officer	[phone]
	www.syntopix.com

Zeus Capital Ltd
Alex Clarkson / Tom Rowley	Tel: [phone]
	www.zeuscapital.co.uk

Media enquiries:

Abchurch Communications
Sarah Hollins / Simone Elviss / Claire Dickinson	Tel: [phone]
[e-mail]	www.abchurch-group.com

Notes to editors

Syntopix is a specialised research and development company, focusing on topical antimicrobial innovations for the cosmetic, consumer healthcare and pharmaceutical markets. The Group was founded in 2003 as a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the world's leading experts in skin microbiology.

Syntopix combines scientific excellence with an understanding of consumer need to identify and develop innovative compounds which have clinical efficacy and proven benefits for the treatment of acne, gingivitis and body odour. 

The Group has a robust research pipeline, with a growing library of over 2,700 compounds (with established safety profiles) profiled both individually and in combination for their antimicrobial activity. The Group, which currently has 12 granted UK patent applications, raised £2 million in March 2010 to undertake clinical studies with its lead compounds and to further develop the pipeline.

The Group's development activities centre on several lead compounds which have multiple potential uses across a number of large consumer healthcare markets including skincare, body odour and oral health. The lead compound, SYN1113, a naturally derived cosmetic ingredient and lead acne treatment candidate, has been shown in the laboratory to be as potent as the market leader (benzoyl peroxide) and will be trialled in volunteers soon. The Group is actively seeking to out-licence its technologies to commercial partners.

Syntopix's shareholders include IP Group plc, The Wellcome Trust Limited, The University of Leeds and Ridings Early Growth Investment Company Limited.  Syntopix joined the AIM market of the London Stock Exchange in March 2006. For more information, please visit our website at www.syntopix.com.

- Ends -

 

END

 

 

RAGURUORAUAAUAR